Professor Cassandra Berry
BSc (Hons) (UWA), PhD (UWA)

Professor - Immunology

About me

I graduated with a double major in microbiology and biochemistry (BSc Hons) at The University of Western Australia and then completed my PhD (UWA) in microbiology (1987). I have extensive experience in medical research with over 30 years working in Australia (UWA) and America (National Institutes of Health, Bethesda, MD). My major research areas are vaccines and immunotherapies for infectious diseases. Special interests in influenza virus, herpesvirus and human immunodeficiency virus. I teach undergraduate units in medical microbiology, clinical immunology and research skills.

 

Previous appointments

Research Director, Integrated Health Research Institute

National Director Australian Society for Medical Research

Deputy Director Centre for Biomolecular Control of Disease

Senior Research Officer, NHMRC, Department of Microbiology, University of WA

Senior Research Officer, NHMRC, Australian Neuromuscular Research Institute,WA

Visiting Associate (Fogarty International USA), National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

Research Officer, Department of Medicine, University of WA

 

Visiting Fellowships

Visiting Professor, Monash Institute of Medical Research, Monash University, Vic.

Uniklinikum Essen Fellowship, Immunomodulation, Emden, Germany

 

International Committee memberships

Publications Committee, International Society for Interferons and Cytokine Research

Membership Committee, International Society for Interferons and Cytokine Research

 

National Committee memberships

Local Organising Committee for International Society for Interferons and Cytokine Research Conferences in Cairns and Melbourne.

National Advisory Council, Lorne Infection and Immunity Conference, Vic.

Australasian Society for Immunology Conference in Perth WA, Treasurer

 

State Committee memberships

Fulbright Selection Committee WA, Australian-American Commission

Conference Organising Committee, Australasian Society for Immunology, Perth.

WA Biomedical Research Institute

WA State Committee, Australian Society for Medical Research

Bursary Committee, Australian Federation of University Women

Combined Biological Sciences meetings in Perth, Secretary

Scientific Advisory Board member, Pest Animal Control CRC

Editorial Board member, Immunology and Cell Biology Journal

 

Teaching area

I co-ordinate and teach the following undergraduate units:

BMS212 MEDICAL MICROBIOLOGY

BMS322 CLINICAL IMMUNOLOGY

BSC200 RESEARCH IN THE PHYSICAL AND LIFE SCIENCES

Research areas

Research interests are within the field of vaccines and immunotherapies for infectious and autoimmune diseases, in particular innate immunity and immunopathology of influenza and herpes viruses.

Current projects

Universal vaccines eliciting broadly neutralising anti-viral antibodies for protection against influenza virus

Antibody responses to EBV epitopes in multiple sclerosis patients

Innate immune activation in HIV-1 infected and treated patients

 

 

Awards and grants

Awards

Runner-Up for the WA Inventor of the Year Awards, Innovative Avian Influenza Marker Vaccine

Finalist for the Vice Chancellor’s Awards of Excellence in Supervision

Finalist for the WA State Telstra Business Women’s Awards

Nominated for the Commonwealth Health Minister’s Awards for Excellence in Health and Medical Research

Nominated for Vice Chancellor’s Awards of Excellence in Teaching

Travel award, Vienna, Austria, International Society for Interferon and Cytokine Research Meeting

Travel award, Turin, Italy, International Society for Interferon and Cytokine Research Meeting

Travel award, Jerusalem, Israel, International Society for Interferon and Cytokine Research Meeting

Athelston and Amy Saw Medical Research Fellowship, University of WA

WA and MG Saw Medical Research Fellowship, University of WA

Commonwealth Postgraduate Research Scholarship, Australia

First prize Glaxo essay competition, Australian Society for Microbiology

Major Grants

Over AUS$4.5 million procured in research income.

2011-13         McCusker Charitable Foundation, Leading Scientist, Interaction between environment and genes on the prevalence, pathogenesis and phenotypes of multiple sclerosis in WA; and career support for early career researchers, (AUS$900,000)

2011-15         ARC Discovery, Associate Investigator with N Mangan, The role of a novel protein, interferon epsilon, in reproductive tract immunity, (AUS$799,855)

2011-13         NHMRC, Associate Investigator with N Mangan and P Hertzog, The role of a novel cytokine of the innate immune response in infection, (AUS$322,524)

2007-08         Commercial Ready Grants, COMET, Chief Investigator A with T Ellis and S Fenwick, Avian influenza marker vaccines for poultry, (AUS$214,000)

2006-08         Stone Ridge Ventures, CI with T Ellis and S Fenwick, Exogenous markers for avian influenza vaccination, ($500,000)

2000-02         NHMRC, Sole Chief Investigator, Cell-mediated immune responses in cytomegalovirus-induced myocarditis, (AUS$234,079)

1999-01         NHMRC, Chief Investigator A with M Beilharz, Therapeutic antiviral efficacies of type I interferon subtypes: delivery and mechanisms of action, (AUS$351,189)

1991-93         Fogarty Visiting Associate, National Institutes of Health, Recipient,  Development of live attenuated influenza virus vaccines, (US$250,000)

 

Events and speaking engagements

Experienced in delivering lectures to large audiences (approx. 300 undergraduate students) and presenting research findings to international scientific groups at specialised research conferences.

Key oral presentations
  • “Novel interferon-lambda therapy for cytomegalovirus myocarditis-the heart of the matter” Invited Seminar, The Advanced Heart Failure and Cardiac Transplant Service, Royal Perth Hospital, Perth, 7th July 2011
  •  “Role of the novel cytokine IFN-epsilon in the innate immune response to infection” Invited Seminar, School of Pathology and Laboratory Medicine, UWA, Royal Perth Hospital Unit, Perth, 24th June 2011
  • “Avian influenza- a need to flock together” Invited Seminar, Monash Institute of Medical Research, Melbourne, February 2009
  • “Influenza vaccines and interferons” Invited Seminar, University of Queensland, Brisbane, January 2009
  • Avian influenza- a need to flock together” Invited Seminar, School of Medicine, Department of Microbiology, University of Otago, Dunedin, NZ, July 2008
  • “Interferons- from immunotherapy to vaccines for viral diseases” Invited Seminar, Johannes Gutenberg University, Mainz, Germany, 23rd August 1998
  • Invited Seminar, Walter and Eliza Hall Institute, Melbourne, 1998
  • Invited Seminar, Johns Hopkins University, Baltimore, USA, 1996
  • Invited Seminar, Duke University, Durham, USA, 1993
  • Seminar, National Institutes of Health, Bethesda, USA, 1992
Conference proceedings

Note name change Lawson= James= Berry

  • Chuang L-W, Huang W-H, Hung J-H, James C, Chen DS, Chen P-J, Huang M-H. (2010). Age-dependent regulation of anti-HBV immunity by type I interferon signaling pathway. International Congress of Immunology, Kobe, Japan.
  • James CM, Fenwick SG, Ellis T. (2008). A novel biomarker of avian influenza vaccination in poultry for use in H5N1 surveillance. Australasian Society for Immunology, Perth Immunology Group Meeting, Perth, Western Australia, Australia.
  • Gerlach N, Gibbert K, Nair S, James, C, Dittmer U. (2008). Induction of IFN alpha subtypes by TLR agonists and their potency for antiretroviral therapy.  Immunology Congress, Vienna, Austria.
  • James CM, Mansfield J, Middleton D, Fenwick S, Ellis T. (2008). Tetanus toxoid as a positive marker for avian influenza vaccination in poultry. Avian Immunology Research Group, Gold Coast, Queensland, Australia.
  • Berry CM, Stumbles P, Gibbs G, Mansfield J, Lisciandro J, Gerlach N, Dittmer U. (2008). Anti-influenza viral effects of type I interferon subtypes in vivo and differential stimulation of dendritic cell activation, antigen processing and presentation to T cells. Innate Sculpting of Adaptive Immunity, Hamilton Island, Queensland, Australia.
  • James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM. (2007). Use of tetanus toxoid as a DIVA (differentiating infected from vaccinated animals) strategy for sero-surveillance of avian influenza virus vaccination in poultry. Options for the Control of Avian Influenza, Toronto, Canada.
  • James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM. (2007). Sero-surveillance of avian influenza virus vaccination in ducks using tetanus toxoid as a DIVA strategy. Options for the Control of Avian Influenza, Toronto, Canada.
  • James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM. (2007). Use of tetanus toxoid as a DIVA (differentiating infected from vaccinated animals) strategy for sero-surveillance of avian influenza virus vaccination in poultry. Combined Biological Sciences 17th Annual Meeting, Perth, Australia.
  • Foong YY, James CM, Mansfield JP, Fenwick SG, Ellis TM. (2007). Sero-surveillance of avian influenza virus vaccination in ducks using tetanus toxoid as a DIVA strategy. Combined Biological Sciences 17th Annual Meeting, Perth, Australia.
  • Rezazadeh Vind A, Foong YY, Mansfield JP, James CM, (2007). A novel DIVA (differentiating infected from vaccinated) strategy with influenza vaccination in ducks. Australian Society for Medical Research, Annual Medical Research Symposium, Perth, Australia.
  • James CM, Lisciandro J, Gerlach, N, Dittmer, U, Stumbles, P. (2007). Interferon-alpha subtypes differentially enhance dendritic cell biology. International Society for Interferon and Cytokine Research Annual Meeting, Oxford, England.
  • Gerlach, N, Alter, C, James, CM, and Dittmer, U. (2007). Anti-retroviral effects of type I interferon subtypes in vivo. International Society for Interferon and Cytokine Research Annual Meeting, Oxford, England.
  • Fenwick, SG, James CM, Foong, YY, Mansfield, JP, Ellis TM. (2007). The use of tetanus toxoid for sero-surveillance of avian influenza virus vaccination in poultry. Conference on Emerging Zoonoses, Limassol, Cyprus.
  • James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM. (2007). Evaluation of tetanus toxoid as a positive marker for avian influenza vaccination of poultry- efficacy in vaccine/H5N1 challenge study. Vaccine Congress, Amsterdam, The Netherlands.
  • James, CM, Abdad, MY, Mansfield, JP, Jacobsen, HK, and Bartlett, EJ. (2006). Interferon-alpha transgene treatment enhances protection of DNA vaccinated mice from influenza virus challenge. Advances in Influenza Virus Research: From Birds to Bench to Bedside. Keystone Symposium, Steamboat Springs, Colorado, USA.
  • James, CM, Abdad, MY, Mansfield, JP, Jacobsen, HK, Stumbles, PS, and Bartlett, EJ. (2006). IFN-alpha transgene treatment enhances protection of DNA vaccinated mice from influenza virus challenge. Australasian Vaccines and Immunotherapeutics Development Meeting, Bio 21 Institute, Melbourne, Australia.
  • James, CM. (2006). Differential efficacies of the type I interferons in immunomodulating disease. Graduiertenkolleg 1045, Immunomodulation and Signal Transduction in Infectious Diseases, Emden, Germany.
  • James CM, Lisciandro JG, Stumbles PA, Abdad MY, Mansfield JP. (2006). Investigation of interferon stimulation of dendritic cells for influenza virus vaccine development. International Society for Interferon and Cytokine Research meeting, Vienna, Austria.
  • Shan S, Edwards J, Ellis T, Fenwick S, James CM. (2006). Development and immunological evaluation of a novel DNA vaccine against avian influenza. National Meeting, CRC-Australian Biosecurity, Cairns, Australia.
  • James, CM, Abdad, MY, Mansfield, JP, Jacobsen, HK, and Bartlett, EJ. (2005). Interferon-alpha 6 adjuvant therapy for improving efficacy of influenza A DNA vaccines. Australasian Society for Immunology Annual Meeting, Melbourne, Vic., Australia.
  • Bozanich, EM, Collins, R, Thamrin, C, James, C, Turner, DJ, Sly, PD. (2004). Acute physiological and cellular response to influenza A infection in mice. Thoracic Society of Australia and NZ, Sydney, Australia.
  • Carr, DJJ, Silverman, R, James, C, and Williams, BRG. (2004). The application of type I interferon transgenes to the cornea as a means to dampen HSV-1-induced pathology. XVI International Congress of Eye Research, Sydney, Australia.
  • Stumbles, P, von Garnier, C, Wikstrom, M, Smith, M, Thomas, J, Napoli, S, Holt, P, James, C. (2004). Kinetics and function of airway mucosal and peripheral lung dendritic cell subsets during primary influenza infection. 8th International Symposium on Dendritic Cells, Brugge, Belgium.
  • Carr, D, and James, C. (2003). Interferon-beta is superior to interferon-alpha species in hindering herpes simplex virus type 1 replication in primary trigeminal ganglion cell cultures. International Psychoneuroimmunology Society Meeting, Amelia Is., USA.
  • Carr, DJJ, and James, CM. (2003). A comparison of type I interferons in antagonizing ocular herpes simplex virus type 1 infection in mice: association with 2’,5’oligoadenylate synthetase expression. American Association of Immunologists Meeting, Denver, USA.
  • Cull, VS, Tilbrook, PA, Bartlett, EJ, Brekalo, NL, and James, CM. (2003). Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. International Society for Interferon and Cytokine Research, Cairns, Australia.
  • Bartlett, EJ, Lenzo, JC, Mansfield, JP, Sivamoorthy, S, Cull, VS, and James, CM. (2003). Murine cytomegalovirus-induced myocarditis: modulation of cardiac cytokine expression and cellular infiltration with interferon-alpha therapy. International Society for Interferon and Cytokine Research, Cairns, Australia.
  • Stumbles, PA, Smith, M, Tobagus, I, Thomas, JA, Bozanich, L, Turner, D, Sly, PD, James, CM, Holt, PG. (2003). Influenza infection and the post-natal development of mouse respiratory APC. Australasian Society for Immunology, Perth, Australia.
  • Carr, DJJ, Cull, VS and James, CM. (2002). Mouse cornea tranfected with plasmid containing interferon-beta transgene is superior to other type I interferon transgenes in antagonizing viral-mediated mortality. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, USA.
  • Cull, V, Lenzo, J, Bartlett, E, and James, CM. (2002). Cytomegalovirus infection and autoimmune disease. 8th Australasian Autoimmunity Workshop, Melbourne, Vic.
  • Eade, J, Robertson, I, Lawson, M, Hinds, L, and James, CM. (2002). Naked DNA immunisation of the domestic cat with feline zona pellucia B and C genes. International Symposium on Nonsurgical Contraceptive Methods for Pet Population Control, GA, USA.
  • Cull, V, Broomfield, S, Bartlett, E, Brekalo, N, and James, CM. (2002). Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocardiis in gB DNA-vaccinated mice. International Joint Meeting Cytokines and Interferons, Torino, Italy.
  • Cull, V, Bartlett, E., and Lawson, CM. (2001). The role of type I interferons in induction of adaptive immunity in cytomegalovirus infection. International Congress of Immunology, Stockholm, Sweden
  • Lawson, CM. (2001). Cytomegalovirus-myocarditis: the heart of the matter. Australian Society for Microbiology Annual Scientific Meeting, Perth,WA.
  • Carr, DJJ, Harle, P, AgBaga, M-P, Cull V, and Lawson, CM. (2001). A comparison of the anti-viral efficiacy of murine type I IFN transgene against herpes simplex type 1. International Society for Interferon and Cytokine Research, Maui, Hawaii.
  • Lawson, CM, Cull, VS, and Bartlett, E. (2001). The role of type I interferons in induction of adaptive immunity in cytomegalovirus infection. Australian Society for Medical Research Annual Scientific Meeting, Gold Coast, Qld.
  • Lawson, CM. (2000). Immunocontraception for feral cats. The Australian Veterinary Association Annual Meeting, Perth, W.A.
  • Harle, P, Lawson, CM, Cull, V, Carr, DJ. (2000). Transfections of L929 cells with plasmids encoding for type I interferon confers resistance to herpes simplex virus type 2. International Society of Neurovirology, San Francisco, USA.
  • Cull, V, Tilbrook, PA, Beilharz, MW, Klinken, SP, and Lawson, CM. (2000). Efficacy of type I interferons in J2E cell proliferation, differentiation and development of erythroleukemia. Third Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Amsterdam, Netherlands.
  • Bartlett, E, Cull, V, Beilharz, MW, and Lawson, CM. (2000). Immunisation of mice with DNA encoding type I IFN subtypes protects against cytomegalovirus infection and disease. Third Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Amsterdam, Netherlands.
  • Lenzo, JC, Shellam, GR, and Lawson, CM. (2000). The effect of ganciclovir and cidofovir on cytomegalovirus-induced myocarditis. International Herpesvirus Workshop, Portland, USA.
  • Harle, P, Cull, V, Lawson, C, and Carr, D. (2000). Transfections of L929 cells with plasmid cassettes encoding type I interferon subtypes confers resistance to herpes simplex virus type 2. International Society for Neurovirology Meeting, SF, USA.
  • Lenzo, JC, Shellam, GR, and Lawson, CM. (2000). The role of TNFa in murine cytomegalovirus-induced myocarditis. 30th Annual Conference of The Australasian Society for Immunology, Sydney, NSW.
  • Bartlett, E, Cull, V, Beilharz, MW, and Lawson, CM. (2000). Type I interferon DNA vaccines protect against cytomegalovirus infection. 39th National Scientific Conference, Australian Society for Medical Research, Melbourne, Vic.
  • Fairweather, D, Kaya, Z, Shellam, GR, Lawson, CM, and Rose, NR. (2000). From infection to autoimmunity. World Health Organisation Meeting on Autoimmunity, Geneva, Switzerland.
  • Broomfield, S, Cull,V, and Lawson, CM. (2000). Vaccination of mice against cytomegalovirus using DNA encoding viral envelope glycoprotein B and interferon-beta. Combined Biological Sciences Meeting, Perth, WA.
  • Krishnamurthy, P, Lawson, CM, and Allan, JE. (2000). Effects of virus vaccination on the development of cytomegalovirus-induced myocarditis. Combined Biological Sciences Meeting, Perth, WA
  • Bartlett, E, Cull, V, Beilharz, MW and Lawson, CM. (2000). Type I interferon DNA vaccines protect against cytomegalovirus. Combined Biological Sciences Meeting, Perth, WA
  • Bosio E, Lawson, CM, and Beilharz, MW. (1999). Routes of low dose IFN administration and heart disease. Congress of the International Society for Interferon and Cytokine Research, Paris, France.
  • Lenzo, JC, Shellam, GR, and Lawson, CM. (1999). Therapeutic effects of ganciclovir and foscarnet on cytomegalovirus-induced myocarditis. International Congress of Virology, Sydney, NSW.
  • Lenzo, JC, Fairweather, D, Shellam, GR, and Lawson, CM. (1999). Immunomodulation of cytomegalovirus-induced myocarditis in mice resistant to cardiovascular disease. The Australasian Society for Immunology Meeting, Dunedin, New Zealand.
  • Cull, V, Bartlett, E, Beilharz, MW, and Lawson, CM. (1999). Immunization of mice with DNA encoding various type I interferons protects against cytomegalovirus infection and disease. The Australasian Society for Immunology Meeting, Dunedin, New Zealand.
  • Bosio, E, Lawson, CM, and Beilharz, MW. (1999). Routes of low dose IFN administration and heart disease. Combined Biological Sciences Meeting, Perth, WA.
  • Lenzo, JC, Shellam, GR, and Lawson, CM. (1999). Anti-viral therapies for cytomegalovirus-induced myocarditis. Combined Biological Sciences Meeting, Perth, WA.
Conference proceedings prior to Murdoch
  • Lawson, CM, and Beilharz, MW. (1998). Low-dose oral interferon inhibits virally induced myocarditis. International Society for Interferon and Cytokine Research Meeting, Jerusalem, Israel.
  • Beilharz, MW, and Lawson, CM. (1998). Cytokine gene therapy: intramuscular injection of interferon expression constructs. International Society for Interferon and Cytokine Research Meeting, Jerusalem, Israel.
  • Lawson, CM, and Beilharz, MW. (1998). Cytokine gene therapy for viral myocarditis: naked DNA encoding interferon-alpha 1. The Australasian Society for Immunology Meeting, Melbourne, Victoria.
  • Beilharz, MW, and Lawson, CM. (1998). Suppression of viral myocarditis by intramuscular immunization with naked DNA expressing the interferon alpha 1 transgene. Combined Biological Sciences Meeting, Perth, WA.
  • Lawson, CM, and Beilharz, MW. (1998). Low-dose oral interferon inhibits virally induced myocarditis. Combined Biological Sciences Meeting, Perth,WA.
  • Lenzo, J, Fairweather, D, Singh, B, Shellam, GR, and Lawson, CM. (1998). LPS exacerbates MCMV-induced myocarditis in both susceptible and resistance mouse strains. Combined Biological Sciences Meeting, Perth, WA.
  • Bartlett, E, Beilharz, MW, and Lawson, CM. (1998). Differential transcriptional activation of the interferon-stimulated genes by the individual type I interferon subtypes. Combined Biological Sciences Meeting, Perth, WA.
  • Fairweather, D, Shellam, GR, and Lawson, CM. (1997). Viral and immune mechanisms associated with cytomegalovirus-induced myocarditis. Keystone Symposium, Colorado, USA.
  • Epstein, S, Lo, C-Y, Misplon, J, Lawson, CM, Hendrickson, B, Max, E, and Subbarao, K. (1997). Roles of T cells and J chain-bearing antibodies in protection against heterosubtypic influenza infection in mice. Keystone Symposium, New Mexico, USA.
  • Beilharz, MW, McDonald, W, Watson, M, Heng, J, McGeachie, J, and Lawson, CM. (1997). Low dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. International Society for Interferon and Cytokine Research Meeting, San Diego, USA.
  • Yeow, W-S, Lawson, CM, and Beilharz, MW. (1997). Antiviral activities of individual murine interferon alpha subtypes in vivo. International Society for Interferon and Cytokine Research Meeting, San Diego, USA
  • Lawson, CM, Yeow, W-S, and Beilharz, MW. (1997). Differences in antiviral activities of murine interferon alpha subtypes in vivo. The Australasian Society for Immunology Meeting, Perth, WA.
  • Fairweather, D, Shellam,GR, and Lawson, CM. (1997). Persistence of cytomegalovirus in the heart does not correlate with chronic myocarditis. The Australasian Society for Immunology Meeting, Perth, WA.
  • Lawson, CM. (1997). Cytomegalovirus: myocarditis and therapeutic strategies. The Australasian Society for Immunology Meeting, Perth, WA. Invited symposium.
  • Bosio, E, Lawson, CM, Watson, MW, and Beilharz, MW. (1997). Low dose oral type I interferons reduce early virus replication of murine cytomegalovirus. Combined Biological Sciences Meeting, Perth, WA.
  • Yeow, W-S, Beilharz, MW, and Lawson, CM. (1997). In vivo differences in the antiviral activities of individual murine interferon alpha subtypes. Combined Biological Sciences Meeting, Perth, WA.
  • Fairweather, D, Shellam, GR, and Lawson, CM. (1997). Persistence of cytomegalovirus in the heart does not correlate with chronic myocarditis. Combined Biological Sciences Meeting, Perth, WA.
  • Lawson, CM,Yeow, W-S , Lee,CL, and Beilharz, MW. (1996). Murine type I interferon transgene expression in vivo following intramuscular inoculation of naked DNA. Growth Factor and Signal Transduction Conference, Ames, Iowa, USA.
  • Fairweather, D, Shellam, GR, and Lawson, CM. (1996). MCMV-induced myocarditis:  NK cells protect against and CD4/8 T cells induce disease. The Australasian Society for Immunology, Adelaide, SA.
  • Yeow, W-S, Lawson, CM, and Beilharz, MW. (1996). Over expression of an interferon alpha gene by intramuscular injection of naked DNA. The Australian Society for Medical Research, Gold Coast, Qld.
  • Yeow, W-S, Lawson, CM, Lee, CL, and Beilharz, MW. (1996). Naked DNA transgene expression for murine type I interferons. Combined Biological Sciences Meeting, Perth, WA.
  • Fairweather, D, Shellam, GR, and Lawson, CM. (1996). The role of cytomegalovirus in inflammatory heart disease. Combined Biological Sciences Meeting, Perth, WA.
  • Garlepp, M, Tabbarias, H, Blechynden, L, Lawson, CM, Van Bockxmeer, F, and Mastaglia, F. (1995). Genetic factors in inclusion body myositis. Inclusion Body Myositis Meeting, Marseille, France.
  • Fairweather, D, Chapman, AJ, Booth, TWM, Lawson, CM, Lathbury, LJ, Scalzo, AA, Garlepp, MJ, and Shellam, GR. (1995). Mechanisms of murine cytomegalovirus-induced myocarditis. Australian Society for Microbiology, Sydney, NSW.
  • Lawson, CM, Blechynden, LM, Garlepp, MJ, Sherman, J, and Raben, N. (1995). Naked DNA inoculation of the gene for histidyl-tRNA synthetase: A possible model for autoimmune polymyositis. The Australasian Society for Immunology, Gold Coast, Qld.
  • Blechynden, LM, Lawson, CM, and Garlepp, MJ. (1995). Cloning and sequence characterization of the murine gene for histidyl-tRNA synthetase and its application in a murine model for autoimmune polymyositis. The Australasian Society for Immunology, Gold Coast, Qld.
  • Blechynden, L, Garlepp, M, and Lawson, CM. (1995). Induction of an immune response to plasmid-encoded autoantigen, histidyl-tRNA synthetase by direct gene transfer. Combined Biological Sciences Meeting, Perth, WA.
  • Subbarao, EK, Lawson, CM, and Murphy, BR. (1994). Rescue of mutant derivatives of an influenza A virus PB2 gene confirms that the mutations specify temperature sensitivity. American Society for Virology 13th Annual Meeting, Madison, USA.
  • Epstein, SL, Lo, C-Y, Misplon, JA, Murphy, BR, Lawson, CM, and Subbarao, EK. (1994). Mediators of heterosubtypic immunity to influenza A virus infection of mice. Modern Approaches to New Vaccines including the Prevention of AIDS, Cold Spring Harbor, New York, USA.
  • Lawson, CM, Subbarao, EK, and Murphy, BR. (1994). Influenza viruses with synthetic genes- a new approach to vaccines. Combined Biological Sciences Meeting, Perth, WA.
  • Lawson, CM, Epstein, SL, Misplon, J, Bennink, J, Yewdell, J, and Murphy, BR. (1993). Vaccinia-influenza recombinant viruses protect mice against influenza A virus infection. American Society for Virology 12th Annual Meeting, Davis, USA.
  • Lawson, CM, and Murphy, BR. (1992). Nucleotide sequence changes in live attenuated temperature-sensitive mutants of influenza A/Udorn/307/72 (H3N2) virus. American Society for Virology 11th Annual Meeting, Ithica, USA.
  • Epstein, SL, Misplon, JA, Lawson, CM, Subbarao, EK, and Murphy, BR. (1992). Vaccination with HA- and NA- vaccinia-influenza recombinants provide protective immunity to influenza A virus. Annual Research Festival, National Institutes of Health, MD, USA.
  • Lawson, CM, O’Donoghue, H, and Reed, WD. (1990). Autoantibodies to cardiac myosin in cytomegalovirus myocarditis. VIIIth International Congress of Virology, Berlin, Germany.
  • Lawson, CM, O’Donoghue, H and Reed, WD. (1989). Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. Australian Society for Immunology Annual Scientific Meeting, Adelaide, SA.
  • Lawson, CM, O’Donoghue, H, and Reed, WD. (1989). Cytomegalovirus myocarditis-immunological aspects. Royal Australasian College of Physicians, Perth, WA.
  • Lawson, CM, O’Donoghue, HL and Reed, WD. (1988). Cytomegalovirus and myocarditis in the mouse. Joint Meeting of the Sektion Virologie der Deutschen Gesellschaft fur Hygiene und Mikrobiologie and the Virus Group of the Society for General Microbiology, Hamburg, West Germany.
  • Lawson, CM, O’Donoghue, H , and Reed, WD. (1988). The role of T cells in mouse cytomegalovirus myocarditis. Australian Society for Immunology Annual Scientific Meeting, Brisbane, Qld.
  • Lawson, CM, Grundy, JE and Shellam, GR. (1985). Mediators of genetically-determined resistance to murine cytomegalovirus infection. Australian Society for Microbiology Annual Scientific Meeting, Perth, WA.
  • Lawson, CM, Grundy, JE and Shellam, GR. (1984). Humoral responses to murine cytomegalovirus. Australian Society for Immunology Annual Scientific Meeting, Perth, WA.

Professional and community service

University service

Member, Professorial Promotions and Probationary Review Committee, Murdoch University

Chair, Marketing Committee, Division of Health Sciences, Murdoch University

Chair, Biomedical Science Programme, Murdoch University

Chair, Working Party, Safety and security in science, Murdoch University

Elect member, Academic Council, Murdoch University

Chair, Curriculum and Education Quality Committee, Murdoch University

Member, Promotions and Probationary Review Committee, Murdoch University

Member, Board of Division of Health Sciences, Murdoch University

Member, Board of Research, Murdoch University

Member, Research Committee, Division of Veterinary and Biomedical Sciences, Murdoch University

Member, Animal Users Committee, The University of Western Australia

Community service

As Convenor for Medical Research Week in WA, I coordinated events and led a team of volunteers to present gala dinners with the national Visiting Professor (ASMR medalist), medical research symposiums, public health expos, careers information sessions for secondary school students, workshops for commercialisation of research, and science in art open days.

Chosen as a Real Life Hero for National Science Week.

Promoted medical research and women in science through forums and media engagements, including print, radio and television.

Public lectures

“Vaccinations: Do we really need them?” Alexander Library, Perth

“Celebrating a career plus children” Business Women’s Breakfast Seminar Series, Matilda Bay Restaurant, Perth

“Vaccines for heart disease” Rotary Club, Rockingham

Doctoral and masters supervisions

Completed PhD students

Castley, Alison (2016) Filling the gaps: towards improved surveillance and monitoring of immunological status relevant to long-term co-morbidities in HIV infection. PhD thesis, Murdoch University.

Strautins, Kaija (2016) Investigating the role of Epstein-Barr virus in the pathogenesis of Multiple Sclerosis. PhD thesis, Murdoch University.

Rinaldi, Catherine (2015) Prevention of influenza virus infection using ruminant polyclonal antibodies. PhD thesis, University of Western Australia.

Proal, Amy (2012) Autoimmune disease re-examined in light of metagenomic concepts.PhD thesis, Murdoch University.

Abdad, M. Yazid (2011) An epidemiological and serological study of Rickettsia in Western Australia.  PhD thesis, Murdoch University.

Shan, Songhua (2010) Development and evaluation of DNA vaccines in chickens against a wild bird H6N2 avian influenza virus from Western Australia. PhD thesis, Murdoch University.

Chua, Tze Hoong (2009) Studies on the diagnosis, epidemiology and control of highly pathogenic H5N1 avian influenza. PhD thesis, Murdoch University.

Smuts, Celia (2009) Development of tools to improve the detection of Trypanosoma evansi in Australia. PhD thesis, Murdoch University.

Eade, Jocye A. (2007) Investigating porcine and feline zona pellucida as immunocontraceptive antigens in the female domestic cat. PhD thesis, Murdoch University.

Bartlett, Emmalene J. (2002) Efficacy and immunological mechanisms of type 1 interferon gene therapy in murine cytomegalovirus. PhD thesis, Murdoch University.

Lenzo, Jason (2002) Immunomodulation of cardiovascular disease: murine studies of cytomegalovirus myocarditis. PhD thesis, The University of Western Australia.

Bosio, Erika (2001) Effects of low dose oral administration of type I interferons. PhD thesis, The University of Western Australia.

Fairweather, DeLisa (2000) Viral and immunological pathogenic mechanisms in cytomegalovirus-induced  myocarditis. PhD thesis, The University of Western Australia.

Yeow, Wen-Shuz (1999) The expression and antiviral properties of the individual type I interferon subtypes. PhD thesis, The University of Western Australia.

Honours research students

Back, Chelsea (2011) Ross River virus virulence in Western Australia. Hons thesis, Murdoch University.

Pemberton, Dean (2009) Dendritic cell function and type I interferon subtype production following Ross River virus infection. Hons thesis, Murdoch University.

Rezazadeh Vind, Azita (2007) Avian influenza vaccination in ducks using tetanus toxoid as a positive marker for vaccination. Hons thesis, Murdoch University.

Lisciandro, Joanne (2006) Investigation of interferon stimulation of dendritic cells for influenza virus vaccine development. Hons thesis, Murdoch University.

Nelson, Jan (2006) Development of mucosal immunity to Streptococcus pneumoniae and haemophilus influenzae in children and the relationship to otitis media and nasopharyngeal carriage. Hons thesis, Murdoch University.

Ward, Vanessa (2005) Immune responses of preterm infants, term infants and adults to group B streptococcus and related stimuli. Hons thesis, Murdoch University.

Abdad, M. Yazid (2004) Type I IFN (-alpha 6) enhancement of haemaglutinin DNA vaccine for influenza virus. Hons thesis, Murdoch University.

Archer, Brendon (2003) Protective immunity elicited by IFN/gB CMV DNA vaccine. Hons thesis, Murdoch University.

Irwin, Samantha (2003) Immune responses of maternal and cord blood lymphocytes to neonatal pathogens. Hons thesis, Murdoch University.

Mowe, Eva (2002) Characterisation of interferon and viral gB DNA vaccine mediated protection against cytomegalovirus. Hons thesis, Murdoch University.

Sivamoorthy, Soruba (2002) The role of IFN-alpha 6 DNA therapy in immunomodulation of cytomegalovirus-induced myocarditis. Hons thesis, Murdoch University.

Broomfield, Steve (2000) Vaccination of mice against cytomegalovirus using DNA encoding viral envelope glycoprotein B and interferon-beta. Hons thesis, Murdoch University.

Krishnamurthy, Priya (2000) Effects of virus vaccination on the development of cytomegalovirus-induced myocarditis. Hons thesis, Murdoch University.

Bartlett, Emmalene (1998) Analysis of the role of individual interferon subtypes in the transcription activation of the interferon stimulated genes. Hons thesis, The University of Western Australia.

Bosio, Erika (1997) The mechanism of action of low dose oral type I interferon. Hons thesis, The University of Western Australia.

McDonald, Wade (1996) Are current modes of interferon administration appropriate? Hons thesis, The University of Western Australia.

Publications

Chapters

  • Berry, C., Bartlett, E., Mansfield, J., Cull, V., (2005),Interferon subtype gene therapy for regulating cytomegalovirus disease,In: Methods in Molecular Medicine, Humana Press, pages 207 to 219.

Journals

  • Berry, C., (2017), Antibody immunoprophylaxis and immunotherapy for influenza virus infection: utilization of monoclonal or polyclonal antibodies?, Human Vaccines and Immunotherapeutics, , Aug 30, pages -.
  • Berry, C., (2016), Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System, Cytokine & Growth Factor Reviews, 10.1016/j.cytogfr.2016.08.001, , pages -.
  • Castley, A., Williams, L., James, I., Guelfi, G., Berry, C., Nolan, D., (2016), Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors, PLoS One, 11, 6, pages -.
  • Berry, C., (2015), Towards a universal influenza virus vaccine eliciting broadly neutralising haemagglutinin antibodies, Journal of Vaccines and Vaccination, 6, 5, pages 1000303 -.
  • Rinaldi, C., Penhale, W., Stumbles, P., Tay, G., Berry, C., (2014), Modulation of Innate Immune Responses by Influenza- Specific Ovine Polyclonal Antibodies Used for Prophylaxis, PLoS One, 9, 2, pages e89674 -.
  • Castley, A., Berry, C., French, M., Fernandez, S., Krueger, R., Nolan, D., (2014), Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: A changing paradigm for routine HIV laboratory monitoring?, PLoS One, 9, 12, pages -.
  • Berry, C., Penhale, W., Sangster, M., (2014), Passive Broad-Spectrum Influenza Immunoprophylaxis, Influenza Research and Treatment, 2014, Article ID 267594, pages -.
  • Cha, L., Berry, C., Nolan, D., Castley, A., Fernandez, S., French, M., (2014), Interferon-alpha immune activation and immune dysfunction in treated HIV infection, Clinical and Translational Immunology, 3, e10, pages -.
  • Strickland, D., Fear, V., Shenton, S., Wikstrom, M., Zosky, G., Larcombe, A., Holt, P., Berry, C., von Garnier, C., Stumbles, P., (2014), Persistent and Compartmentalised Disruption of Dendritic Cell Subpopulations in the Lung following Influenza A Virus Infection, PLoS One, 9, 11, pages -.
  • Berry, C., (2013), Vaccine Control of Avian Influenza H5N1 in Poultry: Need for a Positive Marker, Journal of Vaccines and Vaccination, 4, 168, pages 1 - 4.
  • Poinern, G., Ali, N., Berry, C., Singh, P., Fawcett, D., Berchmans, S., (2012), Biocompatibility of Synthesised Nano-Porous Anodic Aluminium Oxide Membranes for Use as a Cell Culture Substrate for Madin-Darby Canine Kidneys Cells: A Preliminary Study, Journal of Tissue Science & Engineering, 3, 3, pages 1 - 7.
  • Le, X., Poinern, G., Ali, N., Berry, C., Fawcett, D., (2012), Engineering a Biocompatible Scaffold withEither Micrometre or Nanometre Scale Surface Topography forPromoting Protein Adsorption and Cellular Response, International Journal of Biomaterials, 201, Article ID 782549, pages 1 - 16.
  • Berry, C., Hertzog, P., Mangan, N., (2012), Interferon as biomarkers and effectors: lessons learned from animal models, Biomarkers in Medicine, 6, 2, pages 159 - 176.
  • Bayer, W., Lietz, R., Ontikatze, T., Johrden, L., Tenbusch, M., Nabi, G., Schimmer, S., Groitl, P., Wolf, H., Berry, C., Überla, K., Dittmer, U., Wildner, O., (2011), Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes, Retrovirology, 8, 1, pages 1 - 15.
  • Berry, C., Mansfield, J., Fenwick, S., Ellis, T., (2010), Use of a tetanus toxoid marker to allow differentiation of infected from vaccinated poultry without affecting the efficacy of a H5N1 avian influenza virus vaccine, Veterinary Record, 167, , pages 695 - 699.
  • Chua, T., Leung, C., Fang, H., Chow, C., Ma, S., Sia, S., Ng, I., Fenwick, S., Berry, C., Chua, S., Chew, S., Kwang, J., Peiris, J., Ellis, T., (2010), Evaluation of a Subunit H5 Vaccine and an Inactivated H5N2 Avian InfluenzaMarker Vaccine in Ducks Challenged with Vietnamese H5N1 Highly Pathogenic Avian Influenza Virus, Influenza Research and Treatment, 2010, 1, pages 1 - 10.
  • Eade, J., Robertson, I., Berry, C., (2009), Contraceptive potential of porcine and feline zona pellucida A, B and C subunits in domestic cats, Reproduction, 137, 6, pages 913 - 922.
  • Gerlach, N., Gibbert, K., Alter, C., Nair, S., Zelinskyy, G., Berry, C., Dittmer, U., (2009), Anti-retroviral effects of type I IFN subtypes in vivo, European Journal of Immunology, 39, 1, pages 136 - 146.
  • Berry, C., Foong, Y., Mansfield, J., Rezazedeh Vind, A., Fenwick, S., Ellis, T., (2008), Evaluation of a positive marker of avian influenza vaccination in ducks for use in H5N1 surveillance., Vaccine, 26, , pages 5345 - 5351.
  • Berry, C., Foong, Y., Mansfield, J., Fenwick, S., Ellis, T., (2007), Use of tetanus toxoid as a differentiating infected from vaccinated animals (DIVA) strategy for sero-surveillance of avian influenza virus vaccination in poultry., Vaccine, 25, 31, pages 5892 - 5901.
  • Berry, C., Abdad, M., Mansfield, J., Jacobsen, H., Rezazedeh Vind, A., Stumbles, P., Bartlett, E., (2007), Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein, Vaccine, 25, 10, pages 1856 - 1867.
  • Austin, B., Berry, C., Harle, P., Carr, D., (2006), Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality, Biological Procedures Online, 8, , pages 55 - 62.
  • Austin, B., Berry, C., Silverman, R., Carr, D., (2005), Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN- during acute ocular herpes simplex virus type 1 infection, Journal of Immunology, 175, 2, pages 1100 - 1106.
  • Bartlett, E., Lenzo, J., Sivamoorthy, S., Mansfield, J., Cull, V., Berry, C., (2004), Type I IFN-b gene therapy suppresses cardiac CD8+T cell infiltration during autoimmune myocarditis, Immunology and Cell Biology, 82, 2, pages 119 - 126.
  • Cull, V., Tilbrook, P., Bartlett, E., Brekalo, N., Berry, C., (2003), Type I interferon differential therapy for erythroleukemia: Specificity of STAT activation, Blood, 101, 7, pages 2727 - 2735.
  • Lenzo, J., Mansfield, J., Sivamoorthy, S., Cull, V., Berry, C., (2003), Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-alpha therapy., Cellular Immunology, 223, , pages 77 - 86.
  • Bartlett, E., Cull, V., Mowe, E., Mansfield, J., Berry, C., (2003), Optimisation of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection., Biological Procedures Online, 5, , pages 43 - 52.
  • Carr, D., Al-Khatib, K., Berry, C., Silverman, R., (2003), Interferon-beta suppresses herpes simplex virus type I-replication in trigemminal ganglion cells through a RNase L-dependent pathway., Journal of Neuroimmunology, 141, , pages 40 - 46.
  • Cull, V., Bartlett, E., Berry, C., (2002), Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis, Immunology: the journal of cells, molecules, system and technologies, 106, , pages 428 - 437.
  • Harle, P., Cull, V., Guo, L., Papin, J., Berry, C., Carr, D., (2002), Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection, Antiviral Research, 56, , pages 39 - 49.
  • Bartlett, E., Cull, V., Brekalo, N., Lenzo, J., Berry, C., (2002), Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection, Immunology and Cell Biology, 80, , pages 425 - 435.
  • Harle, P., Cull, V., Agbaga, M., Silverman, R., Williams, B., Berry, C., Carr, D., (2002), Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication, Journal of Virology, 76, 13, pages 6558 - 6567.
  • Cull, V., Broomfield, S., Bartlett, E., Brekalo, N., Berry, C., (2002), Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice, Gene Therapy (Basingstoke), 9, , pages 1369 - 1378.
  • Lenzo, J., Fairweather, D., Cull, V., Shellam, G., Berry, C., (2002), Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence, Journal of molecular and cellular cardiology, 34, , pages 1 - 12.
  • Lenzo, J., Fairweather, D., Shellam, G., Berry, C., (2001), Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with Lipopolysaccharide and tumor Necrosis Factor, Cellular Immunology, 213, , pages 52 - 61.
  • Lenzo, J., Berry, C., (2001), Cytomegalovirus-induced myocarditis - an animal model for understanding pathogenesis and therapy., International Antiviral News, 9, , pages 166 - 169.
  • Fairweather, D., Kaya, Z., Shellam, G., Berry, C., Rose, N., (2001), From infection to autoimmunity, Journal of Autoimmunity, 16, , pages 175 - 186.
  • Lenzo, J., Shellam, G., Berry, C., (2001), Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice, Antimicrobial Agents and Chemotherapy (Print), 45, 5, pages 1444 - 1449.
  • Berry, C., (2000), Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis, Cellular and Molecular Life Sciences, 57, , pages 552 - 560.
Patents
  • Patent (Australia) (Ellis, T, James, C, Fenwick, S) PCT/ U2006/001682: WO2007/053899,Differentiating Therapeutic Composition, International filing.
  • Patent (USA) (Murphy, BR, Subbarao, K, Lawson, CM, Chanock, R) continuation-in-partto serial no. 07/527,737 for the technology of gene rescue of the polymerase and matrix genes of human influenza viruses in the production of new influenza virus vaccines.
Key publications prior to Murdoch
Chapters
  • Epstein, SL, Lo, C-Y, Misplon, JA, Murphy, BR, Lawson, CM, and Subbarao, EK. (1995).Mediators of heterosubtypic immunity to influenza A virus infection in mice. RM Chanock, F Brown, HS Ginsberg, E. Norling (eds.). InVaccines 95, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY. pp. 393-398.
  • Garlepp, MJ, Blechynden, L, Tabarias, H, Lawson, CM, Van Bockxmeer, F, and Mastaglia, FL. (1998). Genetic factors in sporadic inclusion-body myositis. Askanas V, Serratrice G & Engel, WK (eds). In Inclusion-Body Myositis and Myopathies, Cambridge University Press, pp.177-188.
Journals
  • Lawson, CM, and Beilharz, MW. (1999). Low dose oral use of interferon inhibits virally induced myocarditis. J. Interferon Cytokine Res., 19: 863-867.
  • Bosio, E, Beilharz, MW, Watson, M, and Lawson, CM. (1999). Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J. Interferon Cytokine Res., 19: 869-876.
  • Fairweather, D, Lawson, CM, Chapman, AJ, Brown, CMS, Booth, TWM, Papadimitriou, JM, and Shellam, GR. (1998). Wild isolates of murine cytomegalovirus induce myocarditis and antibodies which cross-react with myosin. Immunol., 94: 263-270.
  • Yeow, W-S, Lawson, CM, and Beilharz, MW. (1998) Antiviral activities of the individual murine interferon alpha subtypes in vivo: Naked DNA expression of interferon transgenes reduces murine cytomegalovirus replication intramuscularly. J. Immunol., 160: 2932-2939.
  • Beilharz, MW, McDonald, W, Watson, M, Heng, J, McGeachie, J, and Lawson, CM. (1997). Low dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res., 17: 625-630.
  • Lawson, CM, Yeow, W-S, Lee, CL, and Beilharz, MW. (1997). In vivo expression of an interferon alpha gene by intramuscular injection of naked DNA. J. Interferon Cytokine Res.,17: 255- 261.
  • Epstein, SL, Lo, C-Y, Misplon, JA, Lawson, CM, Hendrickson, B, Max, EE, and Subbarao, EK. (1997). Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in immunocompetent, T cell-depleted, b2-microglobulin-deficient, and J chain-deficient mice. J. Immunol., 158:1 222-1230.
  • Blechynden, LM, Lawson, MA, Tabarias, H, Garlepp, MJ, Sherman, J, Raben, N, and Lawson, CM. (1997). Myositis induced by naked DNA immunization with the gene for histidyl-tRNA synthetase. Human Gene Therapy, 8: 1469-1480.
  • Blechynden, LM, Lawson, CM, and Garlepp, MJ. (1996). Sequence and polymorphism analysis of the murine gene for histidyl-tRNA synthetase. Gene, 178: 151-156.
  • Subbarao, EK, Park, EJ, Lawson, CM, Chen, AY, and Murphy, BR. (1995). Sequential addition of temperature sensitive missense mutations to the PB2 gene of influenza A transfectant viruses leads to increasing levels of temperature sensitivity and attenuation and permits the rational design of a genetically engineered influenza A virus vaccine. J. Virol., 69: 5969-5977.
  • Lawson, CM, Bennink, JR, Restifo, NP, Yewdell, JW, and Murphy, BR. (1994). Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol., 68: 3505-3511.
  • Epstein, SL, Misplon, JA, Lawson, CM, Subbarao, EK, Connors, M, and Murphy, BR. (1993). ß2-microglobulin-deficient can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J. Immunol., 150: 5484-5493.
  • Lawson, CM, Subbarao, EK, and Murphy, BR. (1992). Nucleotide sequence changes in the polymerase basic protein 2 gene of temperature-sensitive mutants of influenza A virus. Virol. 191: 506-510.
  • Lawson, CM, O’Donoghue, HL, and Reed, WD. (1992). Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin. A model for the study of molecular mimicry in the pathogenesis of viral myocarditis. Immunol., 75: 513-519.
  • Lawson, CM, O’Donoghue, HL, Farrell, HE, Shellam, GR, and Reed, WD. (1991). Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity. Immunol., 72: 427-433.
  • Lawson, CM, O’Donoghue, H, Bartholomaeus, WN, and Reed, WD. (1990). Genetic control of cytomegalovirus induced myocarditis. Immunol., 69:20-26.
  • O’Donoghue, HL, Lawson, CM, and Reed, WD. (1990). Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. Immunol., 71: 20-28.
  • Lawson, CM, Hodgkin, P, and Shellam, GR. (1990). The effect of cyclosporin A on major histocompatibility-linked resistance to murine cytomegalovirus. J. Gen Virol., 70: 1253-1259.
  • Lawson, CM, O’Donoghue, H, and Reed, WD. (1989). The role of T cells in mouse cytomegalovirus myocarditis. Immunol., 67: 132-134.
  • Bartholomaeus, WN, O’Donoghue, H, Foti, D, Lawson, CM, Shellam, GR, and Reed, WD. (1988). Multiple autoantibodies following cytomegalovirus infection: Virus distribution and specificity of autoantibodies. Immunol., 64: 397-405.
  • Lawson, CM, Grundy, JE, and Shellam, GR. (1988). Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J. Gen. Virol., 69: 1987-1998.
  • Lawson, CM, Grundy, JE, and Shellam, GR. (1987). Delayed-type hypersensitivity responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J. Gen. Virol., 68: 2379-2388.